A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia (FIESTA)

NCT03338426 PHASE3 COMPLETED

The objective of this clinical study is to evaluate the efficacy and safety by comparing the fimasartan/atorvastatin treatment group to the fimasartan/placebo treatment group and the placebo/atorvastatin treatment group respectively at Week 8 in patients with essential hypertension and dyslipidemia.

Details

Lead sponsor	Boryung Pharmaceutical Co., Ltd
Phase	PHASE3
Status	COMPLETED
Enrolment	133
Start date	Mon Jan 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Essential Hypertension, Dyslipidemia

Interventions

• Fimasartan 120mg
• Atorvastatin 40mg
• Placebo for Fimasartan 120mg
• Placebo for Atorvastatin 40mg

Countries

South Korea